CryoLife, Inc. (CRY) Director James Benson Sells 2,000 Shares
CryoLife, Inc. (NYSE:CRY) Director James Benson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
CryoLife, Inc. (NYSE:CRY) traded up 1.28% during trading on Thursday, hitting $23.80. The stock had a trading volume of 98,128 shares. The firm has a 50 day moving average of $21.31 and a 200-day moving average of $18.95. The stock has a market cap of $796.01 million, a price-to-earnings ratio of 72.12 and a beta of 0.92. CryoLife, Inc. has a 12 month low of $14.03 and a 12 month high of $23.80.
CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 earnings per share. Equities analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.
Several equities analysts recently issued reports on the company. BidaskClub cut CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $22.33.
Institutional investors and hedge funds have recently made changes to their positions in the company. Municipal Employees Retirement System of Michigan grew its holdings in shares of CryoLife by 3.2% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares during the last quarter. Mason Street Advisors LLC lifted its position in CryoLife by 7.4% during the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 438 shares during the period. State of Alaska Department of Revenue lifted its position in CryoLife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares during the period. First Mercantile Trust Co. lifted its position in CryoLife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares during the period. Finally, Creative Planning lifted its position in CryoLife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the period. 68.44% of the stock is currently owned by hedge funds and other institutional investors.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.